AAAAAA

   
Results: 1-16 |
Results: 16
Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1
Authors: Folkes, A Roe, MB Sohal, S Golec, J Faint, R Brooks, T Charlton, P
Citation: A. Folkes et al., Synthesis and in vitro evaluation of a series of diketopiperazine inhibitors of plasminogen activator inhibitor-1, BIOORG MED, 11(19), 2001, pp. 2589-2592
Manning Clark and the order of Lenin (Reply to Katerina Clark)
Authors: Charlton, P
Citation: P. Charlton, Manning Clark and the order of Lenin (Reply to Katerina Clark), TLS-TIMES L, (5116), 2001, pp. 19-19
Evaluating the deployment of FIPA standards when developing application services
Authors: Charlton, P Cattoni, R
Citation: P. Charlton et R. Cattoni, Evaluating the deployment of FIPA standards when developing application services, INT J PATT, 15(3), 2001, pp. 551-577
Dicationic bis(9-methylphenazine-1-carboxamides): Relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs
Authors: Gamage, SA Spicer, JA Finlay, GJ Stewart, AJ Charlton, P Baguley, BC Denny, WA
Citation: Sa. Gamage et al., Dicationic bis(9-methylphenazine-1-carboxamides): Relationships between biological activity and linker chain structure for a series of potent topoisomerase targeted anticancer drugs, J MED CHEM, 44(9), 2001, pp. 1407-1415
Polymerization of plasminogen activator inhibitor-1
Authors: Zhou, A Faint, R Charlton, P Dafforn, TR Carrell, RW Lomas, DA
Citation: A. Zhou et al., Polymerization of plasminogen activator inhibitor-1, J BIOL CHEM, 276(12), 2001, pp. 9115-9122
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576
Authors: Mistry, P Stewart, AJ Dangerfield, W Okiji, S Liddle, C Bootle, D Plumb, JA Templeton, D Charlton, P
Citation: P. Mistry et al., In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576, CANCER RES, 61(2), 2001, pp. 749-758
Communication between multiple drug binding sites on P-glycoprotein
Authors: Martin, C Berridge, G Higgins, CF Mistry, P Charlton, P Callaghan, R
Citation: C. Martin et al., Communication between multiple drug binding sites on P-glycoprotein, MOLEC PHARM, 58(3), 2000, pp. 624-632
Guanine specific binding at a DNA junction formed by d[CG(5-BrU)ACG]2 witha topoisomerase poison in the presence of Co2+ ions
Authors: Thorpe, JH Hobbs, JR Todd, AK Denny, WA Charlton, P Cardin, CJ
Citation: Jh. Thorpe et al., Guanine specific binding at a DNA junction formed by d[CG(5-BrU)ACG]2 witha topoisomerase poison in the presence of Co2+ ions, BIOCHEM, 39(49), 2000, pp. 15055-15061
Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis
Authors: Martin, C Berridge, G Mistry, P Higgins, C Charlton, P Callaghan, R
Citation: C. Martin et al., Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis, BIOCHEM, 39(39), 2000, pp. 11901-11906
An investigation into the formation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells
Authors: Padget, K Stewart, A Charlton, P Tilby, MJ Austin, CA
Citation: K. Padget et al., An investigation into the formation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]-3-hydroxy-7H-indeno[2,1-c]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells, BIOCH PHARM, 60(6), 2000, pp. 817-821
Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives
Authors: Roe, M Folkes, A Ashworth, P Brumwell, J Chima, L Hunjan, S Pretswell, I Dangerfield, W Ryder, H Charlton, P
Citation: M. Roe et al., Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives, BIOORG MED, 9(4), 1999, pp. 595-600
Preliminary clinical experience of a contracture correction device
Authors: Charlton, P Ferguson, D Peacock, C Stallard, J
Citation: P. Charlton et al., Preliminary clinical experience of a contracture correction device, PROS ORTHOT, 23(2), 1999, pp. 163-168
The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein
Authors: Martin, C Berridge, G Mistry, P Higgins, C Charlton, P Callaghan, R
Citation: C. Martin et al., The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein, BR J PHARM, 128(2), 1999, pp. 403-411
In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance
Authors: Mistry, P Plumb, J Eccles, S Watson, S Dale, I Ryder, H Box, G Charlton, P Templeton, D Bevan, PB
Citation: P. Mistry et al., In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance, BR J CANC, 79(11-12), 1999, pp. 1672-1678
Comparison of low-dose epidural with combined spinal-epidural analgesia for labour
Authors: Dresner, M Bamber, J Calow, C Freeman, J Charlton, P
Citation: M. Dresner et al., Comparison of low-dose epidural with combined spinal-epidural analgesia for labour, BR J ANAEST, 83(5), 1999, pp. 756-760
Analgesia after intracranial surgery: a double-blind, prospective comparison of codeine and tramadol
Authors: Jeffrey, HM Charlton, P Mellor, DJ Moss, E Vucevic, M
Citation: Hm. Jeffrey et al., Analgesia after intracranial surgery: a double-blind, prospective comparison of codeine and tramadol, BR J ANAEST, 83(2), 1999, pp. 245-249
Risultati: 1-16 |